Walters v. Flint

District Court, E.D. Michigan·Decided December 1, 2021·No. 5:17-cv-10164·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MICHIGAN SOUTHERN DIVISION

In re Flint Water Cases Judith E. Levy United States District Judge

__________________________________/

This Order Relates To:

Bellwether I Cases Case No. 17-10164 __________________________________/ OPINION AND ORDER GRANTING IN PART AND DENYING IN PART DEFENDANTS VEOLIA NORTH AMERICA, LLC, VEOLIA NORTH AMERICA, INC., AND VEOLIA WATER NORTH AMERICA OPERATING SERVICES, LLC’S MOTION TO EXCLUDE THE TESTIMONY AND REPORT OF DR. JOSEPH GRAZIANO [338]

This opinion is one in a series addressing the admissibility of the testimony and reports of eight experts retained by Plaintiffs in anticipation of the first bellwether trial, currently set to begin on February 15, 2022. Defendants argue that none of these experts can meet the standards set by Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). Currently before the Court is the motion by Veolia North America, LLC, Veolia North America, Inc., and Veolia Water North America

Operating Services, LLC (collectively “VNA”) to exclude the testimony and report of Dr. Joseph Graziano (ECF No. 338.) The LAN and LAD

Defendants join VNA’s motion. (ECF No. 344.) For the reasons set forth below, VNA’s motion to exclude is GRANTED IN PART and DENIED IN PART.

I. Background Dr. Joseph Graziano is a Professor of Environmental Health Sciences and Pharmacology at Columbia University. (ECF No. 369-3,

PageID.23631.) Dr. Graziano holds a Ph.D. in physiology and is a leading expert on the effects of metal-poisoning. (ECF No. 369-3, PageID.23630.) He has worked for decades on developing medication to treat lead

poisoning and is the inventor of what is now the standard treatment for lead poisoning. (See ECF No. 433, PageID.33278-33280; PageID.33287- 33292.) Dr. Graziano’s qualifications as an expert are not disputed.

Plaintiffs seek to offer Dr. Graziano as one of their causation experts. They retained Dr. Graziano to determine whether lead-

poisoning can cause the adverse health effects they have experienced, and to write a general report about the medical consequences of exposure to lead. In preparation for his report, Dr. Graziano conducted a

comprehensive literature review. That review covered many studies, but one source in particular is of recurring importance. The Agency for Toxic

Substances and Disease Registry (“ATSDR”)1 has published a Toxicological Profile of Lead which contains an exhaustive review of decades of academic work on the harmful effects of lead. Agency for Toxic

Substances and Disease Registry, Toxicological Profile for Lead (Aug. 2020) (https://www.atsdr.cdc.gov/ToxProfiles/tp13.pdf) (“Toxicological Profile”). The Toxicological Profile is one of the most thorough and

authoritative sources available on the topic of lead-poisoning. Dr. Graziano’s primary conclusion is that “overwhelming” scientific

evidence proves that lead poisoning harms the intellectual and neurobehavioral functioning of children. (ECF No. 330-32, PageID.15424.) That conclusion is supported by the Toxicological Profile,

which itself reviews 40 longitudinal studies on lead’s neurocognitive

1 The ATSDR is the federal agency directed to implement certain provisions of the Comprehensive Environmental Response, Compensation and Liability Act. See 42 U.S.C. §9604(i) (setting forth responsibilities of the ATSDR). The preparing of toxicological profiles is one of those responsibilities. See id. at §9604(i)(3). effects in children. See Toxicological Profile, at 140-176.2 But Dr. Graziano also finds support for his conclusion elsewhere. For instance, a

2005 study found by a 95% confidence level that every 1g/dl increase in blood lead corresponded to a -2.9 change in full-scale IQ. Bruce P.

Lanphear et al., Low-level environmental lead exposure and children's intellectual function: an international pooled analysis, 113 Environ Health Perspect. 894-899 (2005) (“Lanphear (2005)”). Dr. Graziano

concludes that any “undue exposure” to lead “is harmful to a child’s intellectual development.” (ECF No. 330-32, PageID.15430.)

Dr. Graziano next emphasizes that the neurological effects of lead- poisoning affect “dimensions of function that go well beyond just intelligence and IQ scores.” (ECF No. 330-32, PageID.15424.) As set forth

in the Toxicological Profile, lead-poisoning is additionally associated with “altered behavior and mood (e.g., attention, hyperactivity, impulsivity, irritability, delinquency) and altered neuromotor and neurosensory

function.” Id. Behavioral effects can include aggression and antisocial behaviors. (Id. at PageID.15427.) Indeed, some studies have found a

2 The Toxicological Profile’s analysis is not limited to blood lead levels. It also reviews studies associating bone lead levels and neurological harms. See Toxicological Profile, at 174-176. direct link between high bone lead content and social, attention, and aggression problems. Herbert L. Needleman et al., Bone lead levels and

delinquent behavior, 275 Jama 363-369 (1996). According to Dr. Graziano, lead-poisoning can also contribute to

other neurological complications, such as schizophrenia and Parkinson’s disease. (ECF No. 330-32, PageID.15425-15426) (citing Ezra B. Susser et al., Prenatal factors and adult mental and physical health. 44 Can. J.

Psychiatry 326-334 (1999); Ezra S. Susser et al., The design of the prenatal determinants of schizophrenia study, 26 Schizophrenia Bull. 257-273 (2000)). Finally, Dr. Graziano notes that exposure to lead can

increase the risk for renal disease and hypertension. (ECF No. 330-32, PageID.15429-15430.)

On May 11, 2021, VNA filed a motion seeking to exclude Dr. Graziano’s opinions. (ECF No. 338.) The Court heard oral argument on

the motion on November 2, 2021. (ECF No. 410.) II. Legal Standard

The admissibility of expert testimony is governed by Federal Rule of Evidence 702, which sets forth three requirements: (1) the witness must be qualified, (2) the testimony must be relevant, and (3) the testimony must be reliable. Fed. R. Evid. 702; In re Scrap Metal Antitrust Litig., 527 F.3d 517, 528–29 (6th Cir. 2008). As the Supreme Court

explained in Daubert, Rule 702 imposes a “gatekeeping” obligation on the courts to ensure that scientific testimony “is not only relevant, but

reliable.” Daubert, 509 U.S. at 589; See also Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 147 (1999). Daubert provides a non-exclusive list of factors courts may consider

when evaluating reliability: (1) whether the theory or technique at the basis of the opinion is testable or has been tested, (2) whether it has been published and subjected to peer review, (3) what the known error rates

are, and (4) whether the theory or technique is generally accepted. Daubert, 509 U.S. at 593; see also In re Scrap Metal, 527 F.3d at 529 (listing same factors). Not every factor needs to be present in every

Free access — add to your briefcase to read the full text and ask questions with AI

Walters v. Flint, (E.D. Mich. 2021).

Walters v. Flint (Walters v. Flint) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wells v. SmithKline Beecham Corp.
601 F.3d 375 (Fifth Circuit, 2010)
Johnny C. McClain v. Metabolife International, Inc
401 F.3d 1233 (Eleventh Circuit, 2005)
Erie Railroad v. Tompkins
304 U.S. 64 (Supreme Court, 1938)
Huddleston v. United States
485 U.S. 681 (Supreme Court, 1988)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Meister, Brenda G. v. Medical Engineering
267 F.3d 1123 (D.C. Circuit, 2001)
Pluck v. BP Oil Pipeline Co.
640 F.3d 671 (Sixth Circuit, 2011)
Bethie Pride v. Bic Corporation Societe Bic, S.A.
218 F.3d 566 (Sixth Circuit, 2000)
In Re Scrap Metal Antitrust Litigation
527 F.3d 517 (Sixth Circuit, 2008)
Henricksen v. ConocoPhillips Co.
605 F. Supp. 2d 1142 (E.D. Washington, 2009)
Larson v. Johns-Manville Sales Corp.
399 N.W.2d 1 (Michigan Supreme Court, 1986)
Prince v. Lott
120 N.W.2d 780 (Michigan Supreme Court, 1963)
In Re Viagra Products Liability Litigation
572 F. Supp. 2d 1071 (D. Minnesota, 2008)
In Re Rezulin Products Liability Litigation
369 F. Supp. 2d 398 (S.D. New York, 2005)
In Re Meridia Products Liability Litigation
328 F. Supp. 2d 791 (N.D. Ohio, 2004)